A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

Percentage of Participants Achieving Complete Remission (CR)

CR is defined according to the modified International Working Group (IWG) criteria for acute myeloid leukemia (AML) as no morphologic evidence of AML and absolute neutrophil count \>=10\^3 /μL (\>=1.0 x 10\^9 /L), platelets \>=10\^5 /μL (\>=100 x 10\^9 /L), red blood cell (RBC) transfusion independence, and bone marrow with \<5% blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.

Time frame: Up to 18 Months

Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (Cri)

Cri is defined according to the modified IWG criteria for AML as all criteria as CR except for residual neutropenia \<10\^3 /μL (1,000/ μL), or thrombocytopenia \<10\^5 /μL (100,000/ μL). If all criteria for CR are meet except for RBC transfusion independence, this also fulfills Cri criteria.

Time frame: Up to 18 Months

Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (CRh)

CRh is defined according to the modified IWG criteria for AML as bone marrow with \< 5% blasts and Peripheral blood neutrophil count of \> 0.5 × 10\^3 /μL and Peripheral blood platelet count of \> 0.5 × 10\^5 /μL and 1-week (\>= 7 days) platelet transfusion-free period prior to the hematology lab collection.

Time frame: Up to 18 Months

Percentage of Participants Achieving Transfusion Independence

Transfusion ndependence is defined as a period of at least 56 days with no transfusion between the first dose of Venetoclax and the last dose of Venetoclax plus 30 days.

Time frame: Up to 18 Months

Event-Free Survival (EFS)

EFS defined as the time from the date of start Venetoclax to the date of morphologic relapse, progressive disease, resistant disease, treatment failure, or death from any cause.

Time frame: Up to 18 Months

Duration of Remission (DOR)

DOR defined as the time from the date of first CR, CRi or CRh to the earliest evidence of morphologic relapse, progressive disease, or death due to disease progression.

Time frame: Up to 18 Months

Duration of Treatment (DoT)

DoT defined as the time from the start of a therapy to the time of treatment discontinuation for any reason.

Time frame: Up to 18 Months

Percentage of participants with Adverse Events (AE)

AE, defined as any unfavorable medical event that is temporarily related to the use of the investigational product, which does not necessarily have a causal relationship with the investigational product.

Time frame: Up to 18 Months

Percentage of participants achieving Minimal Residual Disease (MRD) negativity

MRD negativity, defined as having less than 10\^-3 residual blasts per leukocyte measured in the bone marrow.

Time frame: Up to 18 Months

Change in Health-Related Quality of Life (HRQOL) Score

HRQOL score, defined as a multidimensional construct defined as the subjective perception of the life as a whole, including physical, emotional, social, cognitive functions, disease symptoms and side effects of treatment.

Time frame: Up to 18 Months